Thalidomide

"Thalidomide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.

Descriptor ID	D013792
MeSH Number(s)	D02.241.223.805.810.800 D03.383.621.808.800 D03.633.100.513.750.750
Concept/Terms	Thalidomide Thalidomide Sedoval Sedoval Thalomid Thalomid

Below are MeSH descriptors whose meaning is more general than "Thalidomide".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Carboxylic Acids [D02.241]
Acids, Carbocyclic [D02.241.223]
Phthalic Acids [D02.241.223.805]
Phthalimides [D02.241.223.805.810]
Thalidomide [D02.241.223.805.810.800]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, 1-Ring [D03.383]
Piperidines [D03.383.621]
Piperidones [D03.383.621.808]
Thalidomide [D03.383.621.808.800]
Heterocyclic Compounds, Fused-Ring [D03.633]
Heterocyclic Compounds, 2-Ring [D03.633.100]
Isoindoles [D03.633.100.513]
Phthalimides [D03.633.100.513.750]
Thalidomide [D03.633.100.513.750.750]

Below are MeSH descriptors whose meaning is related to "Thalidomide".

Below are MeSH descriptors whose meaning is more specific than "Thalidomide".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Thalidomide" by people in this website by year, and whether "Thalidomide" was a major or minor topic of these publications.

Bar chart showing 13 publications over 10 distinct years, with a maximum of 2 publications in 2004 and 2013 and 2018

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1997	1	0	1
2004	1	1	2
2005	1	0	1
2012	0	1	1
2013	0	2	2
2014	0	1	1
2018	2	0	2
2019	0	1	1
2021	0	1	1
2023	1	0	1

Below are the most recent publications written about "Thalidomide" by people in Profiles.

Merola JF, Parish LC, Guenther L, Lynde C, Lacour JP, Staubach P, Cheng S, Paris M, Picard H, Deignan C, Jardon S, Chen M, Papp KA. Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: Results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2024 03; 90(3):485-493.

View in: PubMed
Valentine L, Norris MR, Bielory L. Comparison of structural components and functional mechanisms within the skin vs. the conjunctival surface. Curr Opin Allergy Clin Immunol. 2021 10 01; 21(5):472-479.

View in: PubMed
Karadag AS, Parish LC. Sarcoidosis: A great imitator. Clin Dermatol. 2019 May - Jun; 37(3):240-254.

View in: PubMed
Tun HW, Johnston PB, DeAngelis LM, Atherton PJ, Pederson LD, Koenig PA, Reeder CB, Omuro AMP, Schiff D, O'Neill B, Pulido J, Jaeckle KA, Grommes C, Witzig TE. Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma. Blood. 2018 11 22; 132(21):2240-2248.

View in: PubMed
Norris MR, Bielory L. Chronic tearing induced by apremilast. Ann Allergy Asthma Immunol. 2018 09; 121(3):375.

View in: PubMed
Starke RM, Chalouhi N, Jabbour PM, Tjoumakaris SI, Gonzalez LF, Rosenwasser RH, Wada K, Shimada K, Hasan DM, Greig NH, Owens GK, Dumont AS. Critical role of TNF-a in cerebral aneurysm formation and progression to rupture. J Neuroinflammation. 2014 Apr 16; 11:77.

View in: PubMed
Ali MS, Starke RM, Jabbour PM, Tjoumakaris SI, Gonzalez LF, Rosenwasser RH, Owens GK, Koch WJ, Greig NH, Dumont AS. TNF-a induces phenotypic modulation in cerebral vascular smooth muscle cells: implications for cerebral aneurysm pathology. J Cereb Blood Flow Metab. 2013 Oct; 33(10):1564-73.

View in: PubMed
Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen L, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer MA, Naganuma M. Non-Hodgkin's lymphomas, version 1.2013. J Natl Compr Canc Netw. 2013 Mar 01; 11(3):257-72; quiz 273.

View in: PubMed
Lin J, Kelly WK. Targeting angiogenesis as a promising modality for the treatment of prostate cancer. Urol Clin North Am. 2012 Nov; 39(4):547-60.

View in: PubMed
Ozanic Bulic S, Fassihi H, Mellerio JE, McGrath JA, Atherton DJ. Thalidomide in the management of epidermolysis bullosa pruriginosa. Br J Dermatol. 2005 Jun; 152(6):1332-4.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement